Introduction
Medy-Tox Inc., a promising biotech venture based in South Korea, is focused on leveraging its proprietary technologies in the microbial toxin area to develop innovative biotech products. Since its foundation in May 2000, it has been focusing on biopharmaceuticals and other products based on Clostridium botulinum. Its primary business goal is to establish itself as a premier biopharmaceutical firm providing botulinum neurotoxin-related pharmaceuticals and therapeutic/diagnostic antibodies, utilizing its superior science and technology expertise.
Q-Med has entered into a development and commercialisation agreement regarding botulinum toxin products. Q-Med AB and Medy-Tox Inc., a South Korean biopharmaceutical company, have entered into an agreement regarding collaboration with regard to botulinum toxin based biopharmaceuticals.
This collaboration will allow Q-Med to develop and commercialise new generations of botulinum toxin products for both esthetic and therapeutic indications. Medy-Tox will support Q-Med with its extensive technology and know-how in the development of botulinum toxin and Q-Med will support Medy-Tox in the establishment of its new facilities.
What is Neuronox®?
Neuronox® is botulinum toxin type A complex (100 Units) manufactured by Medy-Tox Inc.
Throughout the 1980s and 1990s, Clostridium botulinum had been intensively researched by a group of scientists in Korea. In 2000, the scientists established a biotech venture named ¡°Medy-Tox Inc.¡±, which specializes in botulinum and its toxins. Following much research on biological, biochemical, immunological and toxicity aspects, botulinum toxin type A has been developed as a biopharmaceutical product.
|
|
Neuronox®, the first choice of botulinum toxin type A drug
For last years, many preclinical and clinical studies of Neuronox® have been performed very successfully in Korea as well as other countries. Neuronox® has shown excellent results in therapeutic as well as cosmetic studies. Customers and partners in more than 50 countries have been using Neuronox®.
In 2004 and 2005, Neuronox® has been licensed to famous pharmaceutical companies including Ranbaxy which is one of the biggest generics companies in the world. Ranbaxy will invest significant resources to make Neuronox® a mega brand in India and other countries. Also, a famous Korean pharmaceutical company, CJ Corp., licensed the marketing and sales rights to launch Neuronox® into the Latin and South America of more than 50 countries. All these licensing cases show the credibility of Neuronox®.
Taking into account its efficacy, safety, and price compared with competitive products, Neuronox® is the most welcomed choice of botulinum toxin drug for both doctors and patients in the world.
|
|
|
Specification
The specification of our product is very equivalent and/or superior to those of other competitors. Especially, our extreme focus is on the highest quality control/assurance. |
|
|
|
|
How does Neuronox® work?
Neuronox® blocks neuromuscular transmission binding to acceptor sites on motor nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine.
This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral the successful docking and release of acetylcholine from vesicles situated within nerve endings.
When injected intramuscularly at therapeutic doses, Neuronox® produces partial chemical denervation of the muscle resulting in a localized reduction in muscle activity. In addition, the muscle may atrophy, axonal sprouting may occur, and extra junctional acetlcholine receptors may develop. There is evidence that reinnervation of the muscle may occur, thus slowly reversing muscle denervation produced by Neuronox®. |
|
|
Mechanism of Neuronox® |
|
Clinical Report (1): Essential Blepharospasm
Essential Blepharospasm
Double blinded, randomized, active drug comparative, parallel designed, multi-center, phase ¥² clinical study to evaluate the safety and efficacy of ¡°MEDITOXIN® inj.¡±(The Investigational Drug or Test Drug) in treatment of essential blepharospasm. |
Meditoxin® is another brand name of Neuronox®.
|
| |
"Statistically same efficacy on spasm between Neuronox® and Botox®" |
|
|
Neuronox® |
Botox® |
Screening |
3.46 |
3.38 |
After 4 weeks |
1.85 |
2.12 |
|
|
|
Clinical Report (2): Hemifacial Spasm
Hemifacial Spasm
All the tests were carried out under the regulations of the KFDA (Korean Food & Drug Administration) equivalent to the ICH/WHO guidelines.
The title of the Phase III clinical trial is as follows.
"Double blinded, randomized, active drug comparative, parallel designed, multi-center, phase III clinical study for the safety and the efficacy of MEDITOXIN® inj. in hemifacial spasm patients"
4 major universities & general hospitals participated in the clinical trials. The results were excellent and concluded very successful by the Institutional Review Board of each hospital. |
|
|
